Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are cornerstone therapies in ophthalmology and the mainstay of treatment for many retinal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusions (RVO), and other retinal neovascular diseases. The gene discussed is VEGFA; the disease is wet macular degeneration.